News •

Intravacc to in-license CimCure’s iBoost technology, expanding its vaccine platform portfolio iBoost technology well suited for developing cancer vaccines Joint development of Covid-19 vaccine using iBoost

News •

Intravacc and Leiden University developed an animal replacement method for vaccines. Need for alternatives to animal testing in quality control of vaccines Inactivation of vaccines can be traced without using laboratory animals.

News •

Intravacc and Celonic to develop and produce a novel COVID-19 vaccine Combining Intravacc’s OMV-delivery platform with Covid-19 Spike proteins Preclinical studies to start shortly for candidate selection and inhouse pilot scale GMP production

Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine

Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine Bilthoven, The Netherlands, 25 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, has partnered with American, Buffalo, NY, based Therapyx, to further develop and optimize the world’s first prophylactic vaccine against gonorrhea, NGoXIM. For this…